SMi Reports: James Drinkwater and Olivier Chancel release an invitation chair letter for the Pharmaceutical Microbiology Conference, in London. SMi Group is delighted to present the return of Pharmaceutical Microbiology Conference for its 9th year, […]
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB). The agreement covers a technology that […]
Roche said that the phase 3 PEMPHIX trial of MabThera (rituximab) in moderate to severe pemphigus vulgaris (PV) met its primary endpoint at Week 52. The PEMPHIX trial also showed that MabThera was superior to […]
Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, announced that the Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 & 3 […]
GlaxoSmithKline (GSK) has partnered with US-based biotechnology firm Lyell Immunopharma to develop technologies to boost cancer cell therapies. Under the five-year partnership, GSK’s cell and gene therapy programmes will combine with Lyell’s technologies to maximise […]